No disease-modifying treatment has proven to alter LGMD ... contributed to an equal number of deals. The Limb-Girdle Muscular Dystrophy: Competitive Landscape combines data from the Pharma ...
During the past decade, partnerships were the most frequent type of deal in North America and Asia-Pacific. Meanwhile, in Europe, mergers and licensing agreements contributed to an equal number of ...
Limb-girdle muscular dystrophies constitute a broad range of clinical and genetic entities. We have evaluated 38 autosomal recessive limb-girdle muscular dystrophy (LGMD2) families by linkage analysis ...
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR ...
yet no efficacious treatment is now available. Full functional recovery has been achieved in an entire muscle using AAV vector-mediated gene therapy in a limb girdle muscular dystrophy hamster ...
A woman who developed heart failure due to Duchenne muscular dystrophy (DMD) was diagnosed and treated before she got pregnant ... “Genetic counseling was provided concurrently with the treatment for ...
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. A rare and ...
Reflecting on life this way can lead to profound realizations. For instance, a new couch in our living room recently made me aware that I’m inclined to prioritize the needs of my three sons with ...